Novartis v. Umedica: ENTRESTO® Patent Suit Dismissed Without Prejudice

Case Overview

The Parties

The Patents at Issue

Eight U.S. patents covering ENTRESTO® formulations and compositions were asserted:

• • US8101659B2 (App. No. 12/147570)
• • US11135192B2 (App. No. 15/912701)
• • US9937143B2 (App. No. 15/345941)
• • US9388134B2 (App. No. 14/311788)
• • US11058667B2 (App. No. 15/572399)
• • US11096918B2 (App. No. 16/579581)
• • US9517226B2 (App. No. 14/422855)
• • US8877938B2 (App. No. 11/722360)

These patents span compound chemistry, pharmaceutical compositions, and formulation technologies underlying sacubitril/valsartan combination therapy.

The Accused Product

The accused products were ENTRESTO® tablets in three dosage strengths: 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg — the complete commercially available product line in the U.S. market.

Legal Representation

Novartis was represented by Alexandra M. Joyce and Daniel M. Silver of McCarter & English LLP, a prominent Delaware litigation firm with extensive pharmaceutical patent experience. No defense counsel was entered on record, consistent with the suit’s rapid closure before Umedica was required to respond.

Litigation Timeline & Procedural History

Total Duration: 10 days.

The case was filed in the U.S. District Court for the District of Delaware, the nation’s preeminent venue for pharmaceutical patent litigation. Chief Judge Richard G. Andrews was assigned — a highly experienced Delaware jurist with a substantial Hatch-Waxman docket.

The ten-day lifespan produced no responsive pleadings, no claim construction proceedings, and no substantive rulings. Novartis filed its voluntary dismissal pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure — a unilateral dismissal available before the defendant serves an answer or motion for summary judgment. This procedural mechanism requires no court approval and carries no prejudice to re-filing.

The filing date of December 23, 2024 — immediately preceding a holiday period — and the January 2 dismissal suggest this action may have been filed to preserve a statutory deadline, particularly the 45-day period under Hatch-Waxman triggered upon receipt of a Paragraph IV certification notice.

The Verdict & Legal Analysis

Outcome

The case was dismissed without prejudice at Novartis’s sole initiative. No damages were awarded. No injunctive relief was granted. No findings of infringement or validity were made. The dismissal without prejudice means Novartis explicitly reserves its right to refile identical or related claims against Umedica in the future.

Verdict Cause Analysis

The infringement action was voluntarily withdrawn before Umedica appeared or responded. Because no substantive litigation occurred, there is no judicial analysis of claim construction, validity, or infringement on record. The absence of defense counsel entry further confirms Umedica had not yet formally engaged in the proceeding at the time of dismissal.

The strategic motivations most consistent with this fact pattern include:

1. Hatch-Waxman 45-Day Filing Preservation: Under 21 U.S.C. § 355(j)(5)(B)(iii), brand-name manufacturers must file suit within 45 days of receiving a Paragraph IV ANDA notice to trigger an automatic 30-month FDA approval stay. Filing by the deadline — even if the suit is later withdrawn — may serve specific strategic or negotiation purposes.
2. Settlement or License Negotiations: Early voluntary dismissals in pharmaceutical patent cases frequently reflect concurrent licensing discussions. The dismissal without prejudice preserves leverage while negotiations proceed.
3. Portfolio Refinement: With eight patents asserted, Novartis may have chosen to streamline its patent selection or refine claim theories before formal litigation engagement.

Legal Significance

While this case produced no precedential ruling, its procedural posture carries important doctrinal implications. A Rule 41(a)(1)(A)(i) dismissal without prejudice does not constitute an adjudication on the merits, meaning Novartis faces no res judicata bar to future assertion of these same patents against Umedica. Courts have confirmed this principle consistently across pharmaceutical patent disputes.

The involvement of Judge Richard G. Andrews — had the case proceeded — would have placed it before one of Delaware’s most analytically rigorous patent jurists, relevant for any future re-filing against the same defendant.

Strategic Takeaways

For Patent Holders:

• Filing within statutory Hatch-Waxman deadlines remains critical even when litigation strategy is evolving. Early filing with subsequent dismissal without prejudice maintains future optionality.
• Multi-patent portfolios like Novartis’s eight-patent ENTRESTO® cluster provide assertion flexibility, allowing re-filing with a refined subset of patents.

For Accused Infringers (Generic Manufacturers):

• A dismissal without prejudice is not a victory. Generic manufacturers facing similar early dismissals should continue ANDA prosecution and monitor for re-filing activity closely.
• Failure to enter appearance before dismissal means no attorney fee recovery under 35 U.S.C. § 285 is available.

For R&D Teams:

• ENTRESTO®’s eight-patent fortress portfolio illustrates the layered IP protection strategies that major pharmaceutical companies deploy. Generic developers must conduct comprehensive freedom-to-operate (FTO) analysis spanning compound, formulation, and method-of-use patents before advancing ANDA filings.

Industry & Competitive Implications

ENTRESTO® occupies a dominant commercial position in heart failure pharmacotherapy, and Novartis has aggressively defended its IP estate against generic challengers across multiple ANDA proceedings. The breadth of the asserted portfolio — eight patents spanning application filings from 2007 through 2019 — reflects a deliberate lifecycle management strategy designed to extend market exclusivity well beyond any single patent expiration.

For the generic pharmaceutical industry, this case reinforces the complexity and resource demands of launching ENTRESTO® biosimilar or generic equivalents. Even where an initial suit is dismissed, the unresolved patent landscape and Novartis’s demonstrated willingness to litigate create substantial regulatory and commercial uncertainty.

The choice of Delaware as the litigation venue — consistent with Novartis’s litigation history — signals continued use of this plaintiff-favorable jurisdiction for future enforcement actions. Generic manufacturers and their counsel should anticipate Delaware proceedings as the default forum for any ENTRESTO® ANDA disputes.

Broader licensing trends in the sacubitril/valsartan space will warrant monitoring, as early dismissals sometimes precede formal licensing agreements that reshape generic market entry timelines.

FAQ

What patents were involved in Novartis v. Umedica Laboratories?

Eight U.S. patents were asserted: US8101659B2, US11135192B2, US9937143B2, US9388134B2, US11058667B2, US11096918B2, US9517226B2, and US8877938B2 — all covering ENTRESTO® (sacubitril/valsartan) tablets.

Why was the case dismissed without prejudice so quickly?

Novartis filed a unilateral voluntary dismissal under Rule 41(a)(1)(A)(i) before Umedica responded. This likely reflects Hatch-Waxman deadline compliance, parallel licensing negotiations, or portfolio strategy refinement — and expressly preserves the right to refile.

How does this affect ENTRESTO® generic competition?

The dismissal without prejudice leaves the full patent portfolio available for future enforcement. Generic manufacturers pursuing ENTRESTO® ANDAs should treat this as an active litigation risk, not a resolved matter.

*🔍 View case documents: PACER – Case 1:24-cv-01408 | USPTO Patent Search | Delaware District Court*